<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cells express renin and chymase through which they can activate angiotensin </plain></SENT>
<SENT sid="1" pm="."><plain>Renin expression is induced by <z:e sem="disease" ids="C0851834" disease_type="Disease or Syndrome" abbrv="">hyperglycemic conditions</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>As angiotensinogen is produced in the liver, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells that can activate angiotensin have an enhanced ability to <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasize</z:e> to this organ </plain></SENT>
<SENT sid="3" pm="."><plain>In human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases, patients with <z:mp ids='MP_0002055'>diabetes</z:mp> have higher activities of rennin and <z:chebi fb="0" ids="2719,48432">angiotensin-II</z:chebi> in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, and on average, have a more progressed disease stage, especially with respect to <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>These patients exhibit a stronger association with <z:chebi fb="0" ids="35143">Hemoglobin</z:chebi> A1c levels and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> compared to patients without <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>In a combined <z:mp ids='MP_0002055'>diabetes</z:mp>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> mouse model, concurrent treatment with anti-angiotensin and <z:chebi fb="0" ids="35526">hypoglycemic agents</z:chebi> shows a synergic effect in terms of reduced <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> and improved survival </plain></SENT>
<SENT sid="6" pm="."><plain>The effect of anti-angiotensin treatment and blood sugar control as a baseline management for <z:hpo ids='HP_0003003'>colon cancer</z:hpo> patients with <z:mp ids='MP_0002055'>diabetes</z:mp> needs to be examined in clinical trials to establish whether it can prevent <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
</text></document>